Software & Consulting For The Pharmaceutical Scientist

Home
Contact
Important User Information
Software Products
Downloads
Pricing
Remote Updating System
News
About The Founder
Links
Absorption Rate Constants
Diffusion Coefficients
Manual
Maximum Absorbable Dose
Dissolution Mechanism
Customers
Citations

Hintz RJ, Johnson KC. The effect of particle size distribution on dissolution rate and oral absorption. Int J Pharm. 51 (1989) 9-17.

  1. Johnson KC. Comparison of methods for predicting dissolution and the theoretical implications of particle-size-dependent solubility. J Pharm Sci. DOI 10.1002/jps.22778.

  2. Guo Z, Ma M, Hao Y, Jiang T, Wang S. An investigation on the correlation between drug dissolution properties and the growth behaviour of granules in high shear mixer. Journal of Pharmacy and Pharmacology. 63 (2011) 1548-1558.

  3. Du S, Zhu L, Du B, Shi X, Zhang Z, Wang S, Zhang C. Pharmacokinetic evaluation and antitumor activity of 2-methoxyestradiol nanosuspension. Drug Dev Ind Pharm. (2011) DOI: 10.3109/03639045.2011.609560.

  4. Lo ET, Mattas E, Wei C, Kacsur D, Chen CK. Simultaneous API particle size reduction and polymorph transformation using high shear. Org Process Res Dev. DOI: 10.1021/op2002529.

  5. Michaels JN, Bonsignore H, Hudson-Curtis BL, Laurenz S, Lin H-RH, Mathai T, Pande G, Sheth A, Sprockel O. Attribute-based design space: materials-science-based quality-by design for operational flexibility and process portability. J Pharm Innov. DOI 10.1007/s12247-011-9113-7.

  6. Patel VR, Agrawal YK. Nanosuspension: an approach to enhance solubility of drugs. Journal of Advanced Pharmaceutical Technology & Research. 2 (2011) 81-87.

  7. Quan P, Xia D, Piao H, Piao H, Shi K, Jia Y, Cui F. Nitrendipine nanocrystals: its preparation, characterization, and in vitro-in vivo evaluation. AAPS PharmSciTech. 2011 doi: 10.1208/s12249-011-9682-2.

  8. Howells LM, Berry DP, Elliott PJ, Jacobson EW, Hoffmann E, Hegarty B, Brown K, Steward WP, Gescher AJ. Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases - safety, pharmacokinetics, and pharmacodynamics. Cancer Prev Res. 4 (2011) 1419-1425.

  9. Hughey JR, Keen JM, Brough C, Saeger S, McGinity JW. Thermal processing of a poorly water-soluble drug substance exhibiting a high melting point:  the utility of KinetiSol dispersing. Int J Pharm. 419 (2011) 222-230.

  10. Roush JA. Evaluation of gastrointestinal motility directly from human pharmacokinetic data. Int J Pharm. 419 (2011) 43-51.

  11. Takebe G. Takagi T, Suzuki M, Hiramatsu M. Preparation of polymeric nanoparticles of cyclosporin A using infrared pulsed laser. Int J Pharm. 414 (2011) 244-250.

  12. Gertz M, Houston JB, Galetin A. Physiologically-based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction. Drug Metab Dispos. 39 (2011) 1633-1642.

  13. Wang Y, Li X, Wang L, Xu Y, Cheng X, Wie P. Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery. Int J Nanomedicine. 6 (2011) 1497-1507.

  14. Nagy ZK, AAmir E, Rielly CD. Internal fines removal using population balance model based on control of crystal size distribution under dissolution, growth, and nucleation mechanisms. Cryst Growth Des. 11 (2011) 2205-2219.

  15. Wang L, Liu Z, Liu D, Liu C, Juan Z, Zhang N. Docetaxel-loaded-lipid-based-nanosuspensions (DTX-LNS): preparation, pharmacokinetics, tissue distribution and antitumor activity. Int J Pharm. 413 (2011) 194-201.

  16. Patel DD, Joguparthi V, Wang Z, Anderson BD. Maintainance of supersaturation I: Indomethacin crystal growth kinetic modeling using an online second-derivative ultraviolet spectroscopic method. J Pharm Sci. 100 (2011) 2623-2641.

  17. Šašić S, Yu W, Zhang L. Monitoring of API particle size during solid dosage form manufacturing process by chemical imaging and particle sizing. Analytical Methods 3 (2011) 568-574.

  18. Kougoulos E, Smales I, Verrier HM. Towards integrated drug substance and drug product design for an active pharmaceutical ingredient using particle engineering. AAPS PharmSciTech. 12 (2011) 287-294.

  19. Gao L, Liu G, Wang X, Liu F, Xu Y, Ma J. Preparation of a chemically stable quercetin formulation using nanosuspension technology. Int J Pharm. 404 (2011) 231-237.

  20. Sugano K. Aqueous boundary layers related to oral absorption of a drug: from dissolution of a drug to carrier mediated transport and intestinal wall metabolism. Molecular Pharmaceutics. DOI 10.1021/mp1001119.

  21. Sugano K. Computational oral absorption simulation of free base drugs. Int J Pharm. DOI 10.1016/j.ijpharm.2010.07.027.

  22. Sperry DC, Lobo E, Thomas SJ. Dissolution modeling of bead formulations and predictions of biequivalence for a highly soluble, highly permeable drug. Molecular Pharmaceutics. DOI 10.1021/mp100118t.

  23. Takano R, Takata N, Saito R, Furumoto K, Higo S, Hayashi Y, Machida M, Aso Y, Yamashita S. Quantitative Analysis of the effect of supersaturation on in vivo drug absorption. Molecular Pharmaceutics. DOI 10.1021/mp100109a.

  24. Xia D, Cui F, Piao H, Cun D, Piao H, Jiang Y, Ouyang M, Quan P. Effect of crystal size on the in vitro dissolution and oral absorption of nitrendipine in rats. Pharm Res. DOI 10.1007/s11095-010-0200-0.

  25. Ravichandran R. Development and dissolution velocity studies of an oral albendazole nanocrystal solid formulation. International Journal of Green Nanotechnology: Biomedicine 2 (2010) B99-B110.

  26. Ravichandran R. Formulation of nanosuspensions of gymnemic acids for oral administration. International Journal of Nanoparticles. 3 (2010) 309-325.

  27. Xia D, Quan P, Piao H, Piao H, Sun S, Yin Y, Cui F. Preparation of stable nitrendipine nanosuspensions using the precipitation-ultrasonication method for enhancement of dissolution and oral bioavailability. European Journal of Pharmaceutical Sciences. 40 (2010) 325-334.

  28. Nakarani M, Patel P, Patel J, Patel P, Murthy RSR, Vaghani SS. Cyclosporine A-nanosuspension: formulation, characterization and in vivo comparison with a marketed formulation. Scientia Pharmaceutica. 78 (2010) 345-361.

  29. Deng J, Huang L, Liu F. Understanding the structure and stability of paclitaxel nanocrystals. Int J Pharm. 390 (2010) 242-249.

  30. Yang W, Johnston KP, Williams RO. Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats. European Journal of Pharmaceutics and Biopharmaceutics. 75 (2010) 33-41.

  31. Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling on drug release from controlled drug delivery systems. Acta Poloniae Pharmaceutica - Drug Research. 67 (2010) 217-223.

  32. Gamsiz ED, Miller L, Thombre AG, Ahmed I, Carrier RL. Modeling the influence of cyclodextrins on oral absorption of low-solubility drugs: I. Model development. Biotechnology and Bioengineering. 105 (2010) 409-420.

  33. Tolman JA, Williams RO III. Advances in the Pulmonary Delivery of Poorly Water-Soluble Drugs: Influence of Solubilization on Pharmacokinetic Properties. Drug Dev Ind Pharm. 36 (2010) 1-30.

  34. Kotadia RM, Patel VA, Patel HV. Release Kinetic Study of Controlled-Release Methotrexate Beads by Mathematical Modeling. Research Journal of Pharmaceutical, Biological and Chemical Sciences. 1 (2010) 19-26.

  35. Scully J. Numerical Simulation of the L-glutamic Acid Polymorphic System. PhD Thesis, Department of Mechanical & Aeronautical Engineering, University of Limerick, Ireland (2010).

  36. Takano R, Takata N, Shiraki K, Higo S, Hayashi Y, Yamashita S. A Theoretical-Empirical Analysis on the Initial Dissolution Rate of Drugs from Polydispersed Particles. Biol Pharm Bull. 32 (2009) 1885-1891.

  37. Sugano K. Calculation of Fraction of Dose Absorbed: Comparison Between Analytical Solution Based on One Compartment Steady State Concentration Approximation and Dynamic Seven Compartment Model. Chem-Bio Informatics Journal. 9 (2009) 75-93.

  38. Xiaohui P, Jin S, Mo L, Zhonggui H. Formulation of Nanosuspensions as a new approach for the Delivery of Poorly Soluble Drugs. Current Nanoscience. 5 (2009) 417-427.

  39. Avdeef A, Tsinman K, Tsinman O, Sun N, Voloboy D. Miniaturization of Powder Dissolution Measurement and Estimation of Particle Size. Chemistry & Biodiversity. 6 (2009) 1796-1811.

  40. Jamei M, Turner D, Yang J, Neuhoff S, Polak S, Rostami-Hodjegan A, Tucker G. Population-based mechanistic prediction of oral drug absorption. The AAPS Journal. (2009) DOI: 10.1208/s12248-9099-y.

  41. Golovenko NY, Borisyuk IY. Physiological models of drug bioavailability based on the mechanisms of their absorption. Журн. АМН України. 15 (2009) 32–49.

  42. Sugano K. Introduction to computational oral absorption simulation. Expert Opin Drug Metab Toxicol. 5 (2009) 259-293.

  43. Mauludin R, Müller RH, Keck CM. Development of an oral rutin nanocrystal formulation. Int J Pharm. 370 (2009) 202-209.

  44. Ganta S, Paxton JW, Baguley BC, Garg S. Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. Int J Pharm. 367 (2009) 179-186.

  45. Yang W. Improvement in the Bioavailability of Poorly Water-Soluble Drugs via Pulmonary Delivery of Nanoparticles. Ph.D. Dissertation, The University of Texas at Austin, August 2009.

  46. Sarkar M, Perumal OP, Panchagnula R. Solid-state characterization of nevirapine. Indian J Pharm Sci. 70 (2008) 619-630.

  47. Kesisoglou F, Wu Y. Understanding the effect of API properties on bioavailability through absorption modeling. The AAPS Journal. 10 (2008) 516-525.

  48. Sugano K. Theoretical comparison of hydrodynamic diffusion layer models used for dissolution simulation in drug discovery and development. Int J Pharm. 363 (2008) 73-77.

  49. Takano R, Furumoto K, Shiraki K, Takata N, Hayashi Y, Aso Y, Yamashita S. Rate-limiting steps of oral absorption for poorly water-soluble drugs in dogs; prediction from a miniscale dissolution test and a physiologically-based computer simulation. Pharm Res. 25 (2008) 2334-2344.

  50. Butcher JC, Garg S, Kim D, Sharma P. A modified approach to predict dissolution and absorption of polydisperse powders. Pharm Res. 25 (2008) 2309-2311.

  51. Jinno J, Kamada N, Miyake M, Yamada K, Mukai T, Odomi M, Toguchi H, Liversidge GG, Higaki K, Kimura T. In vitro-in vivo correlation for wet-milled tablet of poorly water-soluble cilostazol. J Control Release. 130 (2008) 29-37.

  52. Yu W, Hancock BC. Evaluation of dynamic image analysis for characterizing pharmaceutical excipient particles. Int J Pharm. 361 (2008) 150-157.

  53. Heng D, Cutler DJ, Chan HK, Yun J, Raper JA. Dissolution kinetic behavior of drug nanoparticles and their conformity to the diffusion model. Langmuir. 24 (2008) 7538-7544.

  54. Sheng JJ, Sirois PJ, Dressman JB, Amidon GL. Particle Diffusional Layer Thickness in a USP Dissolution Apparatus II: A Combined Function of Particle Size and Paddle Speed. J Pharm Sci. 97 (2008) 4815-4829.

  55. Okazaki A, Mano T, Sugano K. Theoretical Dissolution Model of Poly-Disperse Drug Particles in Biorelevant Media. J Pharm Sci. 97 (2008) 1843-1852.

  56. Gao L, Zhang D, Chen M, Duan C, Dai W, Jia L, Zhao W. Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions. Int J Pharm. 355 (2008) 321-327.

  57. Simon LL, Introvigne M, Fischer U, Hungerbűhler. Batch reactor optimization under liquid swelling safety constraint. Chemical Engineering Science. 63 (2008) 770-781.

  58. Simon LL, Nagy ZK, Hungerbuehler. On-line model based control of a safety constrained batch reactor subject to recipe uncertainties. Proceedings of the American Control Conference, 2008, article number 4586730, pages 161-1666.

  59. Ganta S. Development and Evaluation of Nanoparticulate Drug Delivery Systems for Anticancer Drugs.  Ph.D. Thesis, The University of Auckland, New Zealand, 2008.

  60. Sugano K, Okazaki A, Sugimoto S, Tavornvipas S, Omura A, Mano T. Solubility and dissolution profile assessment in drug discovery. Drug Metab Pharmacokinet. 22 (2007) 225-254.

  61. Sheng J. Toward an In Vitro Bioequivalence Test. Ph.D. Dissertation, The University of Michigan 2007.

  62. Takano R, Sugano K, Higashida A, Hayashi Y, Machida M, Aso Y, Yamashita S. Oral Absorption of Poorly Water-Soluble Drugs: Computer Simulation of Fraction Absorbed in Humans from a Miniscale Dissolution Test. Pharm Res. 23 (2006) 1144-56.

  63. Simon LL, Fischer U, Hungerbuhler K. Modeling of a three-phase industrial batch reactor using a hybrid first-principles neural-network model. Ind Eng Chem Res. 45 (2006) 7336-7343.

  64. Cabri W, Ghetti P, Alpegiani M, Pozzi G, Justo-Erbez A, Perez-Martinez JI, Villalon-Rubio R, Monedero-PeralesMC, Munoz-Ruiz A. Cefdinir: a comparative study of anhydrous vs. monohydrate form - microstructure and tabletting behaviour. European Journal of Pharmaceutics and Biopharmaceutics. 64 (2006) 212-221.

  65. Galli C. Experimental determination of the diffusion boundary layer width of micron and submicron particles. Int J Pharm. 313 (2006) 114-122.

  66. Jinno J, Kamada N, Miyake M, Yamada K, Mukai T, Odomi M, Toguchi H, Liversidge GG, Higaki K, Kimura T. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J Control Release. 111 (2006) 56-64.

  67. Mansbach RS, Moore RA. Formulation considerations for the development of medications with abuse potential. Drug and Alcohol Dependence. 83 (supplement 1) (2006) S15-S22.

  68. Hecq J. Deleers M, Fanara D, Vranckx H, Amighi K. Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. Int J Pharm. 299 (2005) 167-77.

  69. Tinke AP, Vanhoutte K, De Maesschalck R, Verheyen S, De Winter H. A new approach in the prediction of the dissolution behavior of suspended particles by means of their particle size distribution. J Pharm Biomed Anal. 39 (2005) 900-7.

  70. Sertsou G. Analytical derivation of time required for dissolution of monodisperse drug particles. J Pharm Sci. 93 (2004) 1941-4.

  71. Bosch HW, Skapin SD, Matijevic E. Preparation and characterization of finely dispersed drugs. 5. Ethyl 3,5-di(acetylamino)-2,4,6-triiodobenzoate. Colloids and Surfaces A: Physicochem. Eng. Aspects. 250 (2004) 43-50.

  72. Balbach S, Korn C. Pharmceutical evaluation of early development candidates "the 100 mg-approach". Int J Pharm. 275 (2004) 1-12.

  73. Lansky P, Lanska V, Weiss M. A stochastic differential equation model for drug dissolution and its parameters. Journal of Controlled Release. 100 (2004) 267-274.

  74. Mohamadi M, Fateh S, Tafaghodinia B. Simulation and Mathemetical modeling of controlled release of Ondansetron.  Presented at the 5th WSEAS International Multiconference on Mathematics and Computers in Biology and Chemistry, 11/15/05 Venice.

  75. Fiese EF. General pharmaceutics - The new physical pharmacy. J Pharm Sci. 92 (2003) 1331-1342.

  76. Laitinen N. Opening new perspectives for visual characterisation of pharmaceutical solids. Doctoral dissertation 2003.  University of Helsinki, Faculty of Science, Department of Pharmacy.

  77. Shan GU, Igarashi K, Ooshima H. Dissolution kinetics of crystals in suspension and its application to L-aspartic acid crystals. Chem Eng J. 288 (2002) 53-8.

  78. Chambin O, Berard V, Rochat-Gonthier MH, Pourcelot Y. Dry absorbed emulsion: 2. Dissolution behaviour of an intricate formulation. Int J Pharm. 235 (2002) 169-178.

  79. Lee MS, Huang CL, Huang SH, Chen YP, Chen CJ, Wen KC. A comparative study on the dissolution profiles of commercial hydrochlorothiazide tablets. Journal of Food and Drug Analysis 10 (2002) 18-24.

  80. Friend DR, Parry GE, Francis T, Kupperblatt G, Chrai SS, Slack G.  Mathematical modeling of a novel controlled-release dosage form.  Drug Delivery Technology 1 (2001) 36-43.

  81. Yu LX. An integrated model for determining causes of poor oral drug absorption.  Pharm Res 16 (1999) 1883-7.

  82. Lee MS, Chang YC, Shih CC, et al. Study on dissolution profile of commercial glyburide tablets.  J  Food Drug Anal. 7 (1999) 83-93.

  83. Carstensen JT, Dali M. Particle size distributions in mesh cuts and microscopically estimated volumetric shape factors. Drug Dev Ind Pharm. 25 (1999) 347-52.

  84. Kalampokis A, Argyrakis P, Macheras P. Heterogeneous tube model for the study of small intestinal flow. Pharm Res. 16 (1999) 87-91.

  85. Dali MV, Carstensen JT. Particle size distributions from multiparticulate dissolution. Drug Dev Ind Pharm. 24 (1998) 637-44.

  86. Curatolo W. Physical chemical properties of oral drug candidates in the discovery and exploratory development settings. PSTT. 1 (1998) 387-93.

  87. Pereira De Almeida L, Simões S, Brito P, Portugal A, Figueiredo M.  Modeling dissolution of sparingly soluble multisized powders. J Pharm Sci. 86 (1997) 726-32.

  88. Chakrabarti S,  Southard MZ. Control of poorly soluble drug dissolution in conditions simulating the gastrointestinal tract flow. 2.  Cocompression of drugs with buffers. J Pharm Sci. 86 (1997) 465-69.

  89. Simões S, Pereira de Almeida L, Figueiredo M. Testing the applicability of classical diffusional models to polydisperse systems. Int J Pharm. 139, (1996) 169-76.

  90. Tromelin A, Habillon S, Andrés C, Pourcelot Y, Chaillot B. Relationship between particle size and dissolution rate of bulk powders and sieving characterized fractions of two qualities of orthoboric acid. Drug Dev Ind Pharm. 22 (9&10) (1996) 977-86.

  91. de Villiers MM. Influence of agglomeration of cohesive particles on the dissolution behaviour of furosemide powder. Int J Pharm. 136 (1996) 175-9.

  92. Yu LX, Crison JR, Amidon GL. Compartmental transit and dispersion model analysis of small intestinal transit flow in humans. Int J Pharm. 140 (1996) 111-8.

  93. Yu LX, E Lipka, Crison JR, Amidon GL. Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. Adv Drug Del Rev. 19 (1996) 359-76.

  94. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 12 (1995) 413-20.

  95. Ueda S, Yamaguchi H, Kotani M, Kimura S, Tokunaga Y, Kagayama A, Hata T. Development of a novel drug release system, time-controlled explosion system (TES). II. Design of multiparticulate TES and in vitro drug release properties. Chem Pharm Bull. 42 (2) (1994) 359-63.

  96. Birat M, Anderberg EK, Barnett MI, Nyström C. Physicochemical aspects of drug release. XV. Investigation of diffusional transport in dissolution of suspended, sparingly soluble drugs. Int J Pharm. 80 (1992) 191-201.

  97. Farin D, Avnir D. Use of fractal geometry to determine effects of surface morphology on drug dissolution.  J Pharm Sci. 81 (1992) 54-7.

  98. Melia CD, Davis SS. Review article: mechanisms of drug release from tablets and capsules. 2. Dissolution. Aliment Pharmacol Therap. 3 (1989) 513-525.

Book citations for Hintz and Johnson

  1. Yang W, Owens DE, Williams RO. Chapter 11 - Pharmaceutical Cryogenic Technologies. Formulating Poorly Water Soluble Drugs. ed. Williams RO, Miller DA, Watts AB. 2012 Springer ISBN 978-1-4614-1143-7.

  2. Matijević E. Chapter 2 - Preparation of Uniform Drug Particles. Fine Particles in Medicine and Pharmacy. ed. Matijević E. 2012 Springer ISBN 978-1-4614-0378-4.

  3. Verma S, Burgess D. Chapter 10 - Solid Nanosuspensions: The Emerging Technology and Pharmaceutical Applications as Nanomedicine. Formulation Suspensions From Formulation Development to Manufacturing. ed. Kulshreshtha AK, Singh ON, Wall GM. 2010 Springer ISBN 978-1-4419-1086-8.

  4. Amidon GE, Secreast PJ, Mudie D. Chapter 8 - Particle, Powder, and Compact Characterization. Developing Solid Oral Dosage Forms: Pharmaceutical Theory & Practice. ed. Qiu Y, Chen Y, Zhang GGZ, Lu L, Porter W. 2009 Elsevier Inc ISBN 9780444532428.

  5. Johansson F, Paterson R. Chapter 21 - Physiologically Based in Silico Models for the Prediction of Oral Drug Absorption. Drug Absorption Studies. ed. Ehrhardt C, Kim KJ. 2008 Springer ISBN 9780387749006.

  6. Lee RW, McShane J, Shaw JM, Wood RW, Shenoy DB.  Chapter 17 - Particle Size Reduction. Water-Insoluble Drug Formulation. 2nd Edition. ed. Liu L, Liu R. 2008 CRC Press. ISBN 0849396441.

  7. Johnson KC. Chapter 1 - Dissolution: Fundamentals of In Vitro Release and the Biopharmaceutics Classification System. Pharmaceutical Product Development In Vitro-In Vivo Correlation. ed. Chilukuri DM, Sunkara G, Young D. 2007 Informa Health Care. ISBN 0849338271.

  8. Ungell AL, Abrahamsson B. Chapter 4 - Biopharmaceutical Support in Candidate Drug Selection. Pharmaceutical Preformulation and Formulation:  A Practical Guide from Candidate Drug Selection to Commercial Dosage Form. Gibson M editor. 2004 Informa Health Care. ISBN 1574911201.

  9. Granero GE, Ramachandran C, Amidon GL. Chapter 8 - Gastrointestinal Dissolution and Absorption of Drugs. Drug Bioavailability: Estimation of Solubility, Permeability, Absorption and Bioavailability. ed. van de Waterbeemd H, Lennernas H, Artursson P. 2003 Wiley-VCH. ISBN 352730438X.

  10. Yu LX, Ellison CD, Hussain AS. Predicting Human Oral Bioavailability using In Silico Models.  Applications of Pharmacokinetic Principles in Drug Development. ed. Krishna R. 2003 Springer. ISBN 0306477661.

  11. Carstensen JT. Advanced Pharmaceutical Solids. 2001 CRC Press. ISBN 0824704312.

  12. Dressman JB. Oral Drug Absorption: Prediction and Assessment. 2000 Informa Health Care. ISBN 0824702727.

  13. Crison JR. Chapter 5 - Biopharmaceutical Aspects of Water-Insoluble Drugs for Oral Drug Delivery. Water-Insoluble Drug Formulation. ed. Liu R. 2000 CRC Press. ISBN 1574911058.

  14. Lee RW, Shaw JM, McShane J, Wood RW. Chapter 13 - Particle Size Reduction. Water-Insoluble Drug Formulation. ed. Liu R. 2000 CRC Press. ISBN 1574911058.

  15. McNamara DP, Vieira ML, Crison JR. Chapter 5 - Dissolution of Pharmaceuticals in Simple and Complex Systems. Transport Processes in Pharmaceutical Systems. ed. Amidon GL, Lee PI, Topp EM. 2000 CRC Press. ISBN 0824766105.

  16. Yu LX, Gatlin L, Amidon GL. Chapter 10 - Predicting Oral Drug Absorption. Transport Processes in Pharmaceutical Systems. ed. Amidon GL, Lee PI, Topp EM. 2000 CRC Press. ISBN 0824766105.

  17. Inskeep PB, Darrington RT. Chapter 1 - Utilization of biopharmaceutical and pharmacokinetic principles in the development of veterinary controlled release drug delivery systems. Controlled Release Veterinary Drug Delivery: Biological and Pharmaceutical Considerations. ed. Rathbone MJ, Gurny R. 2000 Elsevier Science.

  18. Solid-state Chemistry of Drugs. 2nd Edition ed. Byrn SR, Pfeiffer RR, Stowell JG. 1999 SSCI, Inc.

  19. Sinko CM. Chapter 14 - Granulation Characterization: Methods and Significance. Handbook of Pharmaceutical Granulation Technology. ed. Parikh DM. 1997 Marcel Dekker. ISBN 0824798821.

  20. Randall CS. Chapter 6 - Particle Size Distribution. Physical Characterization of Pharmaceutical Solids. Brittain HG. 1995 Informa Health Care. ISBN 0824793722.

  21. Wagner JG. Pharmacokinetics for the Pharmaceutical Scientist. 1993 CRC Press. ISBN 1566760321.

  22. Banakar U. Pharmaceutical Dissolution Testing. 1991 Informa Healthcare. ISBN 0824785673.

Lu ATK, Frisella ME, Johnson KC. Dissolution modeling: factors affecting the dissolution rates of polydisperse powders. Pharm Res. 10 (1993) 1308-14.

  1. Johnson KC. Comparison of methods for predicting dissolution and the theoretical implications of particle-size-dependent solubility. J Pharm Sci. DOI 10.1002/jps.22778.

  2. Nagy ZK, AAmir E, Rielly CD. Internal fines removal using population balance model based on control of crystal size distribution under dissolution, growth, and nucleation mechanisms. Cryst Growth Des. 11 (2011) 2205-2219.

  3. Coutant CA, Skibic MJ, Doddridge GD, Kemp CA, Sperry DC. In vitro monitoring of dissolution of an immediate release tablet by focused beam reflectance. Molecular Pharmaceutics.  DOI 10.1021/mp1001476.

  4. Sperry DC, Lobo E, Thomas SJ. Dissolution modeling of bead formulations and predictions of biequivalence for a highly soluble, highly permeable drug. Molecular Pharmaceutics. DOI 10.1021/mp100118t.

  5. Xia D, Cui F, Piao H, Cun D, Piao H, Jiang Y, Ouyang M, Quan P. Effect of crystal size on the in vitro dissolution and oral absorption of nitrendipine in rats. Pharm Res. DOI 10.1007/s11095-010-0200-0.

  6. Dai W-G. In vitro methods to assess drug precipitation. Int J Pharm. 393 (2010) 1-16.

  7. Scully J. Numerical Simulation of the L-glutamic Acid Polymorphic System. PhD Thesis, Department of Mechanical & Aeronautical Engineering, University of Limerick, Ireland (2010).

  8. Takano R, Takata N, Shiraki K, Higo S, Hayashi Y, Yamashita S. A Theoretical-Empirical Analysis on the Initial Dissolution Rate of Drugs from Polydispersed Particles. Biol Pharm Bull. 32 (2009) 1885-1891.

  9. Avdeef A, Tsinman K, Tsinman O, Sun N, Voloboy D. Miniaturization of Powder Dissolution Measurement and Estimation of Particle Size. Chemistry & Biodiversity. 6 (2009) 1796-1811.

  10. Sugano K. Calculation of Fraction of Dose Absorbed: Comparison Between Analytical Solution Based on One Compartment Steady State Concentration Approximation and Dynamic Seven Compartment Model. Chem-Bio Informatics Journal. 9 (2009) 75-93.

  11. Kesisoglou F, Wu Y. Understanding the effect of API properties on bioavailability through absorption modeling. The AAPS Journal. DOI: 10.1208/s12248-008-9061-4.

  12. Tsinman K, Avdeef A, Tsinman O, Voloboy D. Powder dissolution method for estimating rotating disk intrinsic dissolution rates of low solubility drugs. Pharm Res. 26 (2009) 2093-2100.

  13. Golovenko NY, Borisyuk IY. Physiological models of drug bioavailability based on the mechanisms of their absorption. Журн. АМН України. 15 (2009) 32–49.

  14. Sugano K. Theoretical comparison of hydrodynamic diffusion layer models used for dissolution simulation in drug discovery and development. Int J Pharm. 363 (2008) 73-77.

  15. Butcher JC, Garg S, Kim D, Sharma P. A modified approach to predict dissolution and absorption of polydisperse powders. Pharm Res. 25 (2008) 2309-2311.

  16. Sheng JJ, Sirois PJ, Dressman JB, Amidon GL. Particle Diffusional Layer Thickness in a USP Dissolution Apparatus II: A Combined Function of Particle Size and Paddle Speed. J Pharm Sci. 97 (2008) 4815-4829.

  17. Sugano K, Okazaki A, Sugimoto S, Tavornvipas S, Omura A, Mano T. Solubility and dissolution profile assessment in drug discovery. Drug Metab Pharmacokinet. 22 (2007) 225-254.

  18. Mangin D, Garcia E, Gerard S, Hoff C, Klein JP, Veesler S. Modeling of the dissolution of a pharmaceutical compound. J Cryst Growth 286 (2006) 121-125.

  19. Jinno J, Kamada N, Miyake M, Yamada K, Mukai T, Odomi M, Toguchi H, Liversidge GG, Higaki K, Kimura T. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J Control Release. 111 (2006) 56-64.

  20. Hecq J. Deleers M, Fanara D, Vranckx H, Amighi K. Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. Int J Pharm. 299 (2005) 167-77.

  21. Sertsou G. Analytical derivation of time required for dissolution of monodisperse drug particles. J Pharm Sci. 93 (2004) 1941-4.

  22. Horkovics-Kovats S. Characterization of an active pharmaceutical ingredient by its dissolution properties: amoxicillin trihydrate as a model drug. Chemotherapy 50 (2004) 234-44.

  23. Fiese EF. General pharmaceutics - The new physical pharmacy. J Pharm Sci. 92 (2003) 1331-1342.

  24. Shan GU, Igarashi K, Ooshima H. Dissolution kinetics of crystals in suspension and its application to L-aspartic acid crystals. Chem Eng J. 288 (2002) 53-8.

  25. Webb SD, Koval CA, Randolph CM, Randolph TW. Electrochemical determination of dissolution rates of lyophilized pharmaceutical formulations. Anal Chem 73 (2001) 5296-5301.

  26. Wang JZ, Flanagan DR. General solution for diffusion-controlled dissolution of spherical particles. 1. Theory. J Pharm Sci. 88 (1999) 731-8.

  27. Curatolo W. Physical chemical properties of oral drug candidates in the discovery and exploratory development settings. PSTT. 1 (1998) 387-93.

  28. Okimoto K, Miyake M, Ibuki R, et al. Dissolution mechanism and rate of solid dispersion particles of nilvadipine with hydroxypropylmethylcellulose. Int J Pharm. 159 (1997) 85-93.

  29. Pereira De Almeida L, Simões S, Brito P, Portugal A, Figueiredo M. Modeling dissolution of sparingly soluble multisized powders. J Pharm Sci. 86 (1997) 726-32.

  30. Simões S, Pereira de Almeida L, Figueiredo M. Testing the applicability of classical diffusional models to polydisperse systems. Int J Pharm. 139, (1996) 169-76.

  31. de Villiers MM. Influence of agglomeration of cohesive particles on the dissolution behaviour of furosemide powder. Int J Pharm. 136 (1996) 175-9.

  32. Dali MV, Carstensen JT. Effect of change in shape factor of a single crystal on its dissolution behavior. Pharm Res. 13 (1996) 155-62.

Book citations for Lu, Frisella, and Johnson

  1. Shamblin SL. Chapter 9 - Controlled Release Using Bilayer Osmotic Tablet Technology: Reducing Theory to Practice. Oral Controlled Release Formulation Design and Drug Delivery: Theory to Practice. ed. Wen H, Park K. 2010 John Wiley and Sons. ISBN 9780470253175.

  2. Wang J, Flanagan DR. Chapter 13 - Fundamentals of Dissolution. Developing Solid Oral Dosage Forms: Pharmaceutical Theory & Practice. ed. Qiu Y, Chen Y, Zhang GGZ, Lu L, Porter W. 2009 Elsevier Inc ISBN 9780444532428.

  3. Lee RW, McShane J, Shaw JM, Wood RW, Shenoy DB.  Chapter 17 - Particle Size Reduction. Water-Insoluble Drug Formulation. 2nd Edition. ed. Liu L, Liu R. 2008 CRC Press. ISBN 0849396441.

  4. Johnson KC. Chapter 1 - Dissolution: Fundamentals of In Vitro Release and the Biopharmaceutics Classification System. Pharmaceutical Product Development In Vitro-In Vivo Correlation. ed. Chilukuri DM, Sunkara G, Young D. 2007 Informa Health Care. ISBN 0849338271.

  5. Lee RW, Shaw JM, McShane J, Wood RW. Chapter 13 - Particle Size Reduction. Water-Insoluble Drug Formulation. ed. Liu R. 2000 CRC Press. ISBN 1574911058.

  6. Dressman JB. Oral Drug Absorption: Prediction and Assessment. 2000 Informa Health Care. ISBN 0824702727.

  7. Yu LX, Gatlin L, Amidon GL. Chapter 10 - Predicting Oral Drug Absorption. Transport Processes in Pharmaceutical Systems. ed. Amidon GL, Lee PI, Topp EM. 2000 CRC Press. ISBN 0824766105.

  8. Inskeep PB, Darrington RT. Chapter 1 - Utilization of biopharmaceutical and pharmacokinetic principles in the development of veterinary controlled release drug delivery systems. Controlled Release Veterinary Drug Delivery: Biological and Pharmaceutical Considerations. ed. Rathbone MJ, Gurny R. 2000 Elsevier Science.

  9. Carstensen JT. Pharmaceutical Preformulation. 1998 Informa Health Care. ISBN 9781566766906.

  10. Macheras P, Reppas C, Dressman JB. Biopharmaceutics of Orally Administered Drugs. 1995 Ellis Horwood Limited. ISBN 0131080938.

  11. Wagner JG. Pharmacokinetics for the Pharmaceutical Scientist. 1993 CRC Press. ISBN 1566760321.

Johnson KC, Swindell AC. Guidance in the setting of drug particle size specifications to minimize variability in absorption. Pharm Res. 13 (1996) 1795-8.

  1. Johnson KC. Comparison of methods for predicting dissolution and the theoretical implications of particle-size-dependent solubility. J Pharm Sci. DOI 10.1002/jps.22778.

  2. Di L, Fish PV, Mano T. Bridging solubility between drug discovery and development. Drug Discovery Today. (2011) DOI: 10.1016/j.drudis.2011.11.007.

  3. Beg S, Swain S, Rizwan M, Irfanuddin M, Malini DS. Bioavailability enhancement strategies: basics, formulation approaches and regulatory considerations. Current Drug Delivery. 8 (2011) 691-702.

  4. Lo ET, Mattas E, Wei C, Kacsur D, Chen CK. Simultaneous API particle size reduction and polymorph transformation using high shear. Org Process Res Dev. DOI: 10.1021/op2002529.

  5. Liang C, Gao D, Hubert M, Yin X, Gao C. A boundary-line method for pattern recognition on real particles. Powder Technology. 10 (2011) 155-161.

  6. Chuanxia J, Sai L, Keke W, Yanli G, Na L. Nanoparticles based on hydrophobic alginate derivative as nutraceutical delivery vehicle: vitamin D3 loading. Artificial Cells, Blood Substitutes, and Biotechnology. 2011 DOI: 10.3109/10731199.2011.597759.

  7. Šašić S, Yu W, Zhang L. Monitoring of API particle size during solid dosage form manufacturing process by chemical imaging and particle sizing. Analytical Methods 3 (2011) 568-574.

  8. Kuentz M. Oral self-emulsifying drug delivery systems, from biopharmaceutical to technical formulation aspects. Journal of Drug Delivery Science and Technology. 21 (2011) 17-26.

  9. Van Hoogevest P, Liu X, Fahr A, Leigh MLS. role of phospholipids in the oral and parenteral delivery of poorly water soluble drugs. Journal of Drug Delivery Science and Technology. 21 (2011) 5-16.

  10. Narducci O, Jones AG, Kougoulos E. An assessment of the use of ultrasound in the particle engineering of micrometer-scale adipic acid crystals. Cryst Growth Des. 11 (2011) 1742-1749.

  11. Lu Y, Kim S, Park K. In vitro-in vivo correlation: perspectives on model development. Int J Pharm. doi:10.1016/j.ijpharm.2011.01.010.

  12. Kougoulos E, Smales I, Verrier HM. Towards integrated drug substance and drug product design for an active pharmaceutical ingredient using particle engineering. AAPS PharmSciTech. 12 (2011) 287-294.

  13. Zaki NM, Artursson P, Bergström CAS. A modified physiological BCS for prediction of intestinal absorption in drug discovery. Molecular Pharmaceutics. DOI 10.1021/mp100124f.

  14. Matharu AS, Motto MG, Patel MR, Simonelli AP, Rutesh DH. Evaluation of hydroxypropyl methylcellulose matrix systems as swellable gastro-retentive drug delivery systems (GRDDS). J Pharm Sci. 100 (2011) 150-163.

  15. Sugano K. Possible reduction of effective thickness of intestinal unstirred water layer by particle drifting effect. Int J Pharm. 387 (2010) 103-109.

  16. Benjamin B, Barman TK, Chaira T, Paliwal JK. Integration of physicochemical and pharmacokinetic parameters in lead optimization: a physiological pharmacokinetic model based approach. Current Drug Discovery Technologies. 7 (2010) 143-153.

  17. Singh Y, Singh RA. Insilico studies of organosulfur-functional active compounds in garlic. BioFactors. 36 (2010) 297-311.

  18. Hageman MJ. Performulation designed to enable discovery and assess developability. Combinatorial Chemistry and High Throughput Screening. 13 (2010) 90-100.

  19. Burton PS, Goodwin JT. Solubility and permeability measurement and applications in drug discovery. Combinatorial Chemistry and High Throughput Screening. 13 (2010) 101-111.

  20. Takano R, Takata N, Shiraki K, Higo S, Hayashi Y, Yamashita S. A Theoretical-Empirical Analysis on the Initial Dissolution Rate of Drugs from Polydispersed Particles. Biol Pharm Bull. 32 (2009) 1885-1891.

  21. Avdeef A, Tsinman K, Tsinman O, Sun N, Voloboy D. Miniaturization of Powder Dissolution Measurement and Estimation of Particle Size. Chemistry & Biodiversity. 6 (2009) 1796-1811.

  22. Sugano K. Calculation of Fraction of Dose Absorbed: Comparison Between Analytical Solution Based on One Compartment Steady State Concentration Approximation and Dynamic Seven Compartment Model. Chem-Bio Informatics Journal. 9 (2009) 75-93.

  23. Chu KA, Yalkowsky SH. An interesting relationship between drug absorption and melting point. Int J Pharm. 373 (2009) 24-40.

  24. Chen AZ, Li Y, Chau FT, Lau TY, Hu JY, Zhao Z, Mok DKW. Application of organic nonsolvent in the process of solution-enhanced dispersion by supercritical CO2 to prepare puerarin fine particles. The Journal of Supercritical Fluids. 49 (2009) 394-402.

  25. Fotaki N. Pros and cons of methods used for the prediction of oral drug absorption. Expert Rev Clin Pharmacol. 2 (2009) 195-208.

  26. Sugano K. Introduction to computational oral absorption simulation. Expert Opin Drug Metab Toxicol. 5 (2009) 259-293.

  27. Curatolo W. Nightingale JA. Herbig SM. Utility of hydroxypropylmethylcellulose acetate succinate (HPMCAS) for initiation and maintenance of drug supersaturation in the GI milieu. Pharm Res. 26 (2009) 1419-1431.

  28. Nomeir AA, Morrison R, Prelusky D, Korfmacher W, Broske L, Hesk D, McNamara P, Mei H. Estimation of the extent of oral absorption in animals from oral and intravenous pharmacokinetic data in drug discovery. J Pharm Sci. 98 (2009) 4027-4038.

  29. Martin del Valle EM, Galan MA, Carbonell RG. Drug delivery technologies: the way forward in the new decade. Ind Eng Chem Res 48 (2009) 2475-2486.

  30. Golovenko NY, Borisyuk IY. Physiological models of drug bioavailability based on the mechanisms of their absorption. Журн. АМН України. 15 (2009) 32–49.

  31. Kesisoglou F, Wu Y. Understanding the effect of API properties on bioavailability through absorption modeling. The AAPS Journal. 10 (2008) 516-525.

  32. Parrott N, Lave T. Applications of physiologically based absorption models in drug discovery and development. Molecular Pharmaceutics. 5 (2008) 760-775.

  33. Kuentz M. Drug absorption modeling as a tool to define the strategy in clinical formulation development. The AAPS Journal. 10 (2008) 473-479.

  34. Acosta E. Bioavailability of nanoparticles in nutrient and nutraceutical delivery. Curr Opin Colloid Interface Sci. (2008) doi: 10.1016/j.cocis.2008.01.002.

  35. Butcher JC, Garg S, Kim D, Sharma P. A modified approach to predict dissolution and absorption of polydisperse powders. Pharm Res. 25 (2008) 2309-2311.

  36. Golovenko NY, Borisyuk IY. The biopharmaceutical classification system-experimental model of prediction of drug bioavailability. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry. 2 (2008) 235-244.

  37. Yu W, Hancock BC. Evaluation of dynamic image analysis for characterizing pharmaceutical excipient particles. Int J Pharm. 361 (2008) 150-157.

  38. Papadopoulou V, Valsami G, Dokoumetzidis A, Macheras P. Biopharmaceutics classification systems for new molecular entities (BCS-NMEs) and marketed drugs  (BCS-MD): theoretical basis and practical examples. Int J Pharm. 361 (2008) 70-77.

  39. Brandl M, Wu X, Holper M, Hong L, Jia Z, Birudaraj R, Reddy M, Alfredson T, Tran T. Larrabee S, Hadig X, Sarma K, Washington C, Hill G, Smith DB. Physicochemical properties of the nucleoside prodrug R1626 leading to high oral bioavailability. Drug Dev Ind Pharm. 34 (2008) 683-691.

  40. Okazaki A, Mano T, Sugano K. Theoretical Dissolution Model of Poly-Disperse Drug Particles in Biorelevant Media. J Pharm Sci. 97 (2008) 1843-1852.

  41. Avdeef A, Kansy M, Bendels S, Tsinman K. Absorption-excipient-pH classification gradient maps: Sparingly soluble drugs and the pH partition hypothesis. Eur J Pharm Sci. 33 (2008) 29-41.

  42. Yamashita T, Dohta Y, Nakamura T, Fukami T. High-speed solubility screening assay using ultra-performance liquid chromatography/mass spectrometry in drug discovery. Journal of Chromatography A. 1182 (2008) 72-76.

  43. Alsenz J, Kansy M. High throughput solubility measurement in drug discovery and development. Advanced Drug Delivery Reviews. 59 (2007) 546-567.

  44. Sugano K, Okazaki A, Sugimoto S, Tavornvipas S, Omura A, Mano T. Solubility and dissolution profile assessment in drug discovery. Drug Metab Pharmacokinet. 22 (2007) 225-254.

  45. Fagerholm U. Prediction of human pharmacokinetics - gastrointestinal absorption. Journal of Pharmacy and Pharmacology. 59 (2007) 905-916.

  46. Maas J, Kamm W, Hauck G. An integrated early formulation strategy - from hit evaluation to preclinical candidate profiling. European Journal of Pharmaceutics and Biopharmaceutics. 66 (2007) 1-10.

  47. Stegemann S, Leveiller F, Franchi D, de Jong H, Linden H. When poor solubility becomes an issue: from early stage to proof of concept. European Journal of Pharmaceutical Sciences. 31 (2007) 249-261.

  48. Remenar JF. Improving oral bioavailability through inhibition of crystallization after dosing. American Pharmaceutical Review. 10(2) (2007) 84-9.

  49. Grabowski T. Farmakokinetyka i Biofarmacja. www.biokinetica.pl/farmakokinetyka.pdf

  50. Yalkowsky SH, Johnson JLH, Sanghvi T, Machatha SG. A ‘Rule of Unity’ for Human Intestinal Absorption. Pharm Res. 23 (2006) 2475-81.

  51. Thomas VH, Bhattachar S, Hitchingham L, Zocharski P, Naath M, Surendran N, Stoner CL, El-Kattan A. The road map to oral bioavailability: an industrial perspective. Expert Opin Drug Metab Toxicol. 2 (2006) 591-606.

  52. Renslo AR, Luehr GW, Gordeev MF. Recent developments in the identification of novel oxazolidinone antibacterial agents. Bioorg Med Chem. 14 (2006) 4227-40.

  53. United States Patent 7026508 (2006).

  54. Valko K, Reynolds DP. High-throughput physicochemical and in vitro ADMET screening.  Am J Drug Deliv. 3 (2005) 83-100.

  55. Li S, He H, Parthiban LJ, Yin H, Serajuddin ATM. IV-IVC considerations in the development of immediate-release oral dosage form. J Pharm Sci. 94 (2005) 1396-1417.

  56. Tinke AP, Vanhoutte K, Vanhoutte F, De Smet M, De Winter H. Laser diffraction and image analysis as a supportive analytical tool in the pharmaceutical development of immediate release direct compression formulations. Int J Pharm. 297 (2005) 80-8.

  57. Avdeef A. The rixe of PAMPA. Expert Opin Drug Metab Toxicol. 1 (2005) 325-342.

  58. Avdeef A. Modelling drug absorption with the MAD model, based on permeability and solubility. Clin Exp Pharm Phys. (Suppl) (2004) A29.

  59. Neervannan S. Stategies to impact solubility and dissolution rate during drug lead optimization: salt selection and prodrug design approaches. American Pharmaceutical Review. 7 (2004) 108-13.

  60. Poggesi I. Predicting human pharmacokinetics from preclinical data. Curr Opin Drug Discov Devel. 7 (2004) 100-111.

  61. Rasenack N, Muller BW. Micron-size drug particles: common and novel micronization techniques. Pharm Dev Technol. 9 (2004) 1-13.

  62. Huang LF, Tong WQ. Impact of solid state properties on developability assessment of drug candidates. Adv Drug Deliv Rev, 56 (2004) 321-34.

  63. Singhal D, Curatolo W. Drug polymorphism and dosage form design: a practical perspective. Adv Drug Deliv Rev. 56 (2004) 335-347.

  64. Faassen WA. Biopharmaceutical aspects of oral drug delivery. Doctoral thesis. Utrecht University. 2004.

  65. Martini LG, Crowley PJ. Physicochemical approaches to enhancing oral absorption. Pharmaceutical Technology Europe. Sep 1 2004.

  66. United States Patent 20040044241 (2004).

  67. Tolle-Sander S, Grill A, Joshi H, Kapil R, Persiani S, Polli JE. Characterization of dexloxiglumide in vitro biopharmaceutical properties and active transport. J Pharm Sci. 92 (2003) 1968-80.

  68. Sanghvi T, Ni N, Mayersohn M, Yalkowsky SH. Predicting Passive Intestinal Absorption Using A Single Parameter. QSAR & Combinatorial Science. 22 (2003) 247-257.

  69. Hilgers AR, Smith DP, Biermacher JJ, Day JS, Jensen JL, Sims SM, Adams WJ, Friis JM, Palandra J, Hosley JD, Shobe EM, Burton PS. Predicting Oral Absorption of Drugs: A Case Study with a Novel Class of Antimicrobial Agents. Pharm Res. 20 (2003) 1149-1155.

  70. Fiese EF. General pharmaceutics - The new physical pharmacy. J Pharm Sci. 92 (2003) 1331-1342.

  71. Gombar VK, Silver IS, Zhao Z. Role of ADME Characteristics in Drug Discovery and Their In Silico Evaluation: In Silico Screening of Chemicals for their Metabolic Stability. Curr Top Med Chem. 3 (2003) 1205-1225.

  72. Bergstrom CAS, Strafford M, Lazorova L, Avdeef A, Luthman K, Artursson P. Absorption Classification of Oral Drugs Based on Molecular Surface Properties. J Med Chem. 46 (2003) 558-570.

  73. Laitinen N. Opening new perspectives for visual characterisation of pharmaceutical solids. Doctoral dissertation 2003.  University of Helsinki, Faculty of Science, Department of Pharmacy.

  74. Burton PS, Goodwin JT, Vidmar TJ, Amore BM. Predicting Drug Absorption: How Nature Made It a Difficult Problem. J Pharmacol Exp Ther. 303 (2002) 889-895.

  75. Stenberg P, Bergstrom CAS, Luthman K, Artursson P. Theoretical predictions of drug absorption in drug discovery and development. Clin Pharmcokinet. 41 (2002) 877-899.

  76. Egan WJ, Lauri G. Prediction of intestinal permeability. Adv Drug Deliver Rev. 54 (2002) 273-289.

  77. Andersen K, Buur A. Moderne Laegemiddelforskning. Dansk Kemi. 82 (2001) 40-4.

  78. Stenberg P. Computational models for the prediction of intestinal membrane permeability. Dissertation. Uppsala University. 2001.

  79. Ohm A. Interaction of bay t 3839 coprecipitates with insoluble excipients. Eur J Pharm Biopharm. 49 (2000) 183-9.

  80. Stewart BH, Wang Y, Surendran N. Ex vivo approaches to predicting oral pharmacokinetics in humans. Annu Rep Med Chem. 35 (2000) 299-307.

  81. Blake JF.  Chemoinformatics – predicting the physicochemical properties of “drug-like” molecules. Curr Opin Biotech. 11 (2000) 104-7.

  82. Boxenbaum H. Absorption potential and its variants. Pharm Res. 16 (1999) 1893.

  83. Curatolo W. Physical chemical properties of oral drug candidates in the discovery and exploratory development settings. PSTT. 1 (1998) 387-93.

  84. De Vrueh RLA, Smith PL, Lee CP. Transport of L-valine-acyclovir via the oligopeptide transporter in the human intestinal cell line. J Pharmacol Exp Ther. 286 (1998) 1166-70.

Book citations for Johnson and Swindell

  1. Roberts K, Docherty R, Taylor S. Chapter 13 - Materials Science: Solid Form Design and Crystallisation Process Development. Pharmaceutical Process Development: Current Chemical and Engineering Challenges. ed. Blacker J, Williams MT. 2011 Royal Society of Chemistry ISBN 978-1-84973-146-1.

  2. Huang L, Dong J, Karki S. Chapter 8 - Pharmaceutics Developability Assessment. Evaluation of Drug Candidates for Preclinical Development: Pharmacokinetics, Metabolism, Pharmaceutics, and Toxicology. ed. Han C, Davis CB, Wang B. 2010 Wiley ISBN 978-0-470-04491-9.

  3. Nomeir AA. ADME Strategies in Lead Optimization. Early Drug Development: Strategies and Routes to First-in-Human Trials. ed. Cayen MN. 2010 John Wiley & Sons, Inc. ISBN 9780470170861.

  4. Heikkilä T. Miniaturization of Drug Solubility and Dissolution Testings. Academic Dissertation, Division of Pharmaceutical Technology, Faculty of Pharmacy, University of Helsinki, presented on 6/11/2010.

  5. Davies AM, Bruneau P. Chapter 4 - In Silico Prediction of Solubility. Drug Bioavailability: Estimation of Solubility, Permeability, Absorption and Bioavailability, Volume 40, Second Edition. Ed. van de Waterbeemd H, Testa B. 2009 Whiley-VCH Verlan GmbH & Co.  ISBN 9783527320516.

  6. van de Waterbeemd H. Chapter 5 - Physicochemical Approaches to Drug Absorption. Drug Bioavailability: Estimation of Solubility, Permeability, Absorption and Bioavailability, Volume 40, Second Edition. Ed. van de Waterbeemd H, Testa B. 2009 Whiley-VCH Verlan GmbH & Co.  ISBN 9783527320516.

  7. Johansson F, Paterson R. Chapter 21 - Physiologically Based in Silico Models for the Prediction of Oral Drug Absorption. Drug Absorption Studies. ed. Ehrhardt C, Kim KJ. 2008 Springer ISBN 9780387749006.

  8. Barbour NP, Lipper RA. Chapter 1 - Introduction to biopharmaceutics and its role in drug development. Biopharmaceutics Applications in Drug Development. edited by Krishna R, Yu L. 2008 Springer ISBN 9780387723785.

  9. Tong WQ. Chapter 2 - Molecular and physiochemical properties impacting oral absorption of drugs. Biopharmaceutics Applications in Drug Development. edited by Krishna R, Yu L. 2008 Springer ISBN 9780387723785.

  10. Bowen WE, Wang Q, Wuelfing WP, Thomas DL, Nelson ED, Mao Y, Hill B, Thompson M, Gallagher K, Reed RA. Chapter 9 - A biopharmaceutical classification system approach to dissolution: mechanisms and strategies. Biopharmaceutics Applications in Drug Development. edited by Krishna R, Yu L. 2008 Springer ISBN 9780387723785.

  11. Li S, Royce AE, Serajuddin ATM. Chapter 12 - In vitro-in vivo correlation in dosage form development: case studies. Biopharmaceutics Applications in Drug Development. edited by Krishna R, Yu L. 2008 Springer ISBN 9780387723785.

  12. Wong G, Collins CC. Dissolution Testing in Preformulation in Solid Dosage Form Development edited by Adeyeye MC and Brittain HG. 2008 Informa Health Care.  ISBN 0824758099.

  13. Kerns EH, Di L. Drug-like Properties: Concepts, Structure Design and Methods: From ADME to Toxicity Optimization. 2008 Academic Press ISBN 0123695201.

  14. Acosta E. Testing the effectiveness of nutrient delivery systems in Delivery and controlled release of bioactives in foods and nutraceuticals edited by Garti N.  2008 by Woodhead Publishing.  ISBN 9781845691455.

  15. Vasanthavada M, Serajuddin ATM. Chapter 7 - Lipid-Based Self-Emulsifying Solid Dispersions. Oral Lipid-Based Formulations: Enhancing the Bioavailability of Poorly Water-Soluble Drugs. ed. Hauss DJ. 2007 CRC Press ISBN 0824729455.

  16. Jambhekar SS. Chapter 9 - Physicochemical and Biopharmaceutical Properties of Drug Substances and Pharmacokinetics. Foye's Principles of Medicinal Chemistry. ed. Foye WO, Lemke TL, Williams DA. 2007 Lippincott Williams Wilkins ISBN 0781768799.

  17. van de Waterbeemd H. Chapter 2 - Physicochemical Properties in Drug Profiling. Molecular Drug Properties: Measurement and Prediction. Mannhold R. 2007 Wiley-VCH. ISBN 3527317554.

  18. Tong WQ. Chapter 5 - Practical aspects of solubility determination in pharmaceutical preformulation. Solvent Systems and Their Selection in Pharmaceutics and Biopharmaceutics.  ed. Augustinjns P, Brewster ME. 2007 American Association of Pharmaceutical Scientists. ISBN 9780387691497.

  19. Brewster ME, Mackie C, Noppe M, Lampo A, Loftsson T. Chapter 8 - The use of solubilizing excipients and approaches to generate toxicology vehicles for contemporary drug pipelines. Solvent Systems and Their Selection in Pharmaceutics and Biopharmaceutics.  ed. Augustinjns P, Brewster ME. 2007 American Association of Pharmaceutical Scientists. ISBN 9780387691497.

  20. Li S, Mueller-Zsigmondy M, Yin H. Chapter 4 - The Role of In Vitro-In Vivo Correlation in Product Development and Life Cycle Management. Pharmaceutical Product Development In Vitro-In Vivo Correlation. ed. Chilukuri DM, Sunkara G, Young D. 2007 Informa Health Care. ISBN 0849338271.

  21. Johnson KC. Chapter 1 - Dissolution: Fundamentals of In Vitro Release and the Biopharmaceutics Classification System. Pharmaceutical Product Development In Vitro-In Vivo Correlation. ed. Chilukuri DM, Sunkara G, Young D. 2007 Informa Health Care. ISBN 0849338271.

  22. Petricoul O, Cosson V, Fuseau E, Marchand M. Population models for drug absorption and enterohepatic recycling. Pharmacometrics The Science of Quantitative Pharmacology. Ette EI, Williams PJ editors. 2007 John Wiley & Sons, Inc. ISBN 9780471677833.

  23. van de Waterbeemd H. Property-Based Lead Optimization. Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies. Testa B, Krämer SD, Wunderli-Allenspach H, Folkers G editors. 2006 Verlag Helvetica Chimica Acta/Wiley-VCH. ISBN 3906390357.

  24. Avdeef A. High-Throughput Solubility, Permeability, and the MAD PAMPA Model. Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies. Testa B, Krämer SD, Wunderli-Allenspach H, Folkers G editors. 2006 Verlag Helvetica Chimica Acta/Wiley-VCH. ISBN 3906390357.

  25. Hageman MJ. Chapter 5 - Solubility, Solubilization and Dissolution in Drug Delivery During Lead Optimization. Optimizing the "Drug Like" Properties of Leads in Drug Discovery. ed. Borchardt RT, Kerns EH, Hageman MJ, Thakker DR, Stevens JL. 2006 Springer New York.  ISBN 9780387340562.

  26. Rohrs BR. Chapter 7 - Biopharmaceutics Modeling and the Role of Dose and Formulation on Oral Exposure. Optimizing the "Drug Like" Properties of Leads in Drug Discovery. ed. Borchardt RT, Kerns EH, Hageman MJ, Thakker DR, Stevens JL. 2006 Springer New York.  ISBN 9780387340562.

  27. Di L, Kerns EH. Chapter 8 - Application of Physicochemical Data to Support Lead Optimization by Discovery Teams. Optimizing the "Drug Like" Properties of Leads in Drug Discovery. ed. Borchardt RT, Kerns EH, Hageman MJ, Thakker DR, Stevens JL. 2006 Springer New York.  ISBN 9780387340562.

  28. Burton PS, Poggesi I, Germani M, Goodwin JT. Chapter 9 - Computational Models Supporting Lead Optimization in Drug Discovery. Optimizing the "Drug Like" Properties of Leads in Drug Discovery. ed. Borchardt RT, Kerns EH, Hageman MJ, Thakker DR, Stevens JL. 2006 Springer New York.  ISBN 9780387340562.

  29. Iliadis A, Macheras P. Modeling in Biopharmaceutics, Pharmacokinetics and Pharmacodynamics: Homogeneous and Heterogeneous Approaches. 2006 Springer. ISBN 0387281789.

  30. Chapter 3 - Absorption. Pharmacokinetics and Metabolism in Drug Design. ed. Smith DA, van de Waterbeemd, Walker DK. 2006 Wiley-VCH. ISBN 3527313680.

  31. Pudipeddi M, Serajuddin ATM, Mufson D. Chapter 3 - Integrated Drug Product Development-From Lead Candidate Selection to Life-Cycle Management.  The Process of New Drug Discovery and Development. Smith CG, O'Donnell JT ed. 2006 Informa Health Care. ISBN 0849327792.

  32. Hilfiker R, Blatter F, von Raumer M. Relevance of solid-state properties for pharmaceutical products. Polymorphism: in the Pharmaceutical Industry. ed. Hilfiker R. 2006 Wiley-VCH.  ISBN 3527311467.

  33. Quallich GJ, Chapter 12 - Selection of the Drug Form in Exploratory Development. Fundamentals of Early Clinical Drug Development: From Synthesis Design to Formulation. ed. Abdel-Magid AF, Caron S. 2006 John Wiley & Sons. ISBN-10 0471692786.

  34. Troy DB, Beringer P. Remington: The Science and Practice of Pharmacy. 2005 Lippincott Williams & Wilkins. ISBN 0781746736.

  35. Sathe PM, Raw AS, Ouderkirk LA, Yu LX, Hussain AS. Chapter 8 - Drug product performance, In Vitro. Generic Drug Product Development: Solid Oral Dosage Forms. ed. Shargel L, Kanfer I. 2005 Informa Health Care. ISBN 0824754603.

  36. Lombardo F, Absorption Prediction. Pharmaceutical Profiling in Drug Discovery For Lead Selection. ed. Borchardt RT, Kerns EH, Lipinski CA, Thakker DR, Wang B. 2004 Springer. ISBN 0971176795.

  37. Lipinski C. Chapter 16 - Solubility in the Design of Combinatorial Libraries. Analysis and Purification Methods in Combinatorial Chemistry. ed. Yan B. 2004 John Wiley & Sons, Inc. ISBN 9780471269298.

  38. van de Waterbeemd H. Chapter 1 - Physico-chemical Approaches to Drug Absorption. Drug Bioavailability: Estimation of Solubility, Permeability, Absorption and Bioavailability. ed. van de Waterbeemd H, Lennernas H, Artursson P. 2003 Wiley-VCH. ISBN 352730438X.

  39. van de Waterbeemd H, Jones BC. Chapter 1 - Predicting Oral Absorption and Bioavailability. Progress in Medicinal Chemistry Volume 41. ed. King FD, Oxford AW. 2003 Elsevier Science. ISBN 0444511423.

  40. Granero GE, Ramachandran C, Amidon GL. Chapter 8 - Gastrointestinal Dissolution and Absorption of Drugs. Drug Bioavailability: Estimation of Solubility, Permeability, Absorption and Bioavailability. ed. van de Waterbeemd H, Lennernas H, Artursson P. 2003 Wiley-VCH. ISBN 352730438X.

  41. Crison JR. Chapter 5 - Biopharmaceutical Aspects of Water-Insoluble Drugs for Oral Drug Delivery. Water-Insoluble Drug Formulation. ed. Liu R. 2000 CRC Press. ISBN 1574911058.

  42. McNamara DP, Vieira ML, Crison JR. Chapter 5 - Dissolution of Pharmaceuticals in Simple and Complex Systems. Transport Processes in Pharmaceutical Systems. ed. Amidon GL, Lee PI, Topp EM. 2000 CRC Press. ISBN 0824766105.

  43. Yu LX, Gatlin L, Amidon GL. Chapter 10 - Predicting Oral Drug Absorption. Transport Processes in Pharmaceutical Systems. ed. Amidon GL, Lee PI, Topp EM. 2000 CRC Press. ISBN 0824766105.

  44. Inskeep PB, Darrington RT. Chapter 1 - Utilization of biopharmaceutical and pharmacokinetic principles in the development of veterinary controlled release drug delivery systems. Controlled Release Veterinary Drug Delivery: Biological and Pharmaceutical Considerations. ed. Rathbone MJ, Gurny R. 2000 Elsevier Science.

  45. Lombardo F, Winter SM, Tremaine L, Lowe JA III. The anxieties of drug discovery and development. Integration of Pharmaceutical Discovery and Development: casehistories. ed. Borchardt RT. 1998 Springer. ISBN 0306457431.

Zhang Y, Johnson KC. Effect of drug particle size on content uniformity of low-dose solid dosage forms Int J Pharm. 154 (1997) 179-183.

  1. Nelson P. An approach to particle size stability. Inhalation, August 2011, www.inhalationmag.com.

  2. Nguyen TH, Shen W, Hapgood K. Effect of formulation hydrophobicity on drug distribution in wet granulation. Chemical Engineering Journal, 164 (2010) 330-339.

  3. US Patent, Rasagiline formulations of improved content uniformity, No.: US 7,815,942 B2, Oct. 19, 2010.

  4. Chalapathi V, Yuvaraj TV, Jaganathan A. Formulation of paracetamol tablets using a novel binder isolated from Manihot esculenta.L and its evaluation. International Journal of ChemTech Research, 2 (2010) 406-411.

  5. Huang CY, Ku MS. Prediction of drug particle size and content uniformity in low-dose solid dosage forms. Int J Pharm. 383 (2010) 70-80.

  6. Iacocca RG, Burcham CL, Hilden LR. Particle engineering: A strategy for establishing drug substance physical property specifications during small molecule development. J Pharm Sci. 99 (2010) 51-75.

  7. Morris DG, Truitt BF, Kong A, Leyva N, Luner PE. Influence of formulation composition and processing on the content uniformity of low-dose tablets manufactured at kilogram scale. Pharm Dev Technol. 14 (2009) 451-460.

  8. Allagh TS, Ibrahim YKE, Ojile JE. Drug distribution in granules: effect of diluent and granule size on the distribution of a hydrophilic low dose drug in granules. Nig Journ Pharm Sci. 8 (2009) 32-40.

  9. Yu W, Hancock BC. Evaluation of dynamic image analysis for characterizing pharmaceutical excipient particles. Int J Pharm. 361 (2008) 150-157.

  10. Antal I. The importance of micronization in the design of dosage forms II. Pharmaceutical technological considerations. Acta Pharmaceutica Hungarica. 76 (2006) 149-154.

  11. Tinke AP, K. Vanhoutte, F. Vanhoutte, M. De Smet and H. De Winter Laser diffraction and image analysis as a supportive analytical tool in the pharmaceutical development of immediate release direct compression formulations. Int J Pharm. 297 (2005) 80-8.

  12. Rossetti D, Simons SJR, Pagliai P, Ward R, Fitzpatrick S. Predicting the performance of granulation binders through micro-mechanistic observations. Particle & Particle Systems Characterization. 21 (2004) 284-292.

  13. Simons SJR, Rossetti D, Pagliai P, Ward R, Fitzpatrick S. Predicting the performance of granulation binders through micro-mechanistic observations. Powder Technol. 140 (2004) 280-9.

  14. Lee CC, Chan LW, Heng PW. Use of a fluidized bed hammer mill for size reduction and classification: effects of process variables and starting materials on the particle size distribution of milled lactose batches. Pharm Dev Technol. 8 (2003) 431-42.

  15. Johnson KC. Dissolution and absorption modeling: model expansion to simulate the effects of precipitation, water absorption, longitudinally changing intestinal permeability, and controlled release on drug absorption. Drug Dev Ind Pharm. 29 (2003) 833-42.

  16. Santos JV, Moura TFA, Raffin FN. Spray drying parameters optimization for chitosan microparticles as insulin carrier. Acta Farmaceutica Bonaerense. 22 (2003) 327-333.

  17. Dickhoff BH, de Boer AH, Lambregts D, Frijlink HW. The effect of carrier surface and bulk properties on drug particle detachment from crystalline lactose carrier particles during inhalation, as function of carrier payload and mixing time. Eur J Pharm Biopharm. 56 (2003) 291-302.

  18. Mullarney MP, Hancock BC, Carlson GT, Ladipo DD, Langdon BA. The powder flow and compact mechanical properties of sucrose and three high-intensity sweeteners used in chewable tablets. Int J Pharm. 257 (2003) 227-36.

  19. Houri JJ, Do B, Bernadou JM, Pradeau D, Guyon F. Characteristics and role of particle size analysis in the pharmaceutical industry. STP Pharma Pratiques. 12 (2002) 196-204.

  20. Kornchankul W, Hamed E, Parikh NH, Sakr A. Effect of drug proportion and mixing time on the content uniformity of a low dose drug in a high shear mixer. Pharmazie 57 (2002) 49-53.

  21. Kato Y, Moroshima K, Hashizume M, et al. Further observation of content uniformity of D-alpha-tocopheryl acetate as an oily drug in granules obtained by wet granulation with a high-shear mixer. Drug Dev Ind Pharm. 27 (2001) 781-7.

  22. Prescott JK, Garcia TP. A solid dosage and blend content uniformity troubleshooting diagram. Pharm Technol. 25 (2001) 68-88.

  23. Kornchankul W, Parikh NH, Sakr A. Effect of process variables on the content uniformity of a low dose drug in a high shear mixer. Pharm Ind. 62 (2000) 305-11.

Book citations for Zhang and Johnson

  1. Ku MS. Chapter 4 - Preformulation Consideration for Drugs in Oral CR Formulation. Oral Controlled Release Formulation Design and Drug Delivery: Theory to Practice. ed. Wen H, Park K. 2010 John Wiley and Sons. ISBN 9780470253175.

  2. He X. Chapter 18 - Integration of Physical, Chemical, Mechanical, and Biopharmaceutical Properties in Solid Oral Dosage Form Development. Developing Solid Oral Dosage Forms: Pharmaceutical Theory & Practice. ed. Qiu Y, Chen Y, Zhang GGZ, Lu L, Porter W. 2009 Elsevier Inc ISBN 9780444532428.

  3. Zheng JY. Chapter 2 - Challenges and strategies in formulation development of oral solid low-dose drug products. Formulation and Analytical Development for Low-Dose Oral Drug Products. Zheng J editor. 2009 John Wiley & Sons. ISBN 9780470056097.

  4. Johnson KC. Chapter 3 - Particle size of drug substance and product content uniformity - theoretical considerations. Formulation and Analytical Development for Low-Dose Oral Drug Products. Zheng J editor. 2009 John Wiley & Sons. ISBN 9780470056097.

  5. Zhou JJ, Lipp R.  Chapter 4 - Development of low-dose formulations using fluidized bed granulation. Formulation and Analytical Development for Low-Dose Oral Drug Products. Zheng J editor. 2009 John Wiley & Sons. ISBN 9780470056097.

  6. Am Ende MT, Blackwood DO, Gierer DS, Neu CP. Chapter 6 - Challenges in development and scale-up of low-dose drug products by dry granulation: a case study. Formulation and Analytical Development for Low-Dose Oral Drug Products. Zheng J editor. 2009 John Wiley & Sons. ISBN 9780470056097.

  7. Zheng JY, Ternik RL. Chapter 7 - Development of low-dose solid oral tablets using direct compression. Formulation and Analytical Development for Low-Dose Oral Drug Products. Zheng J editor. 2009 John Wiley & Sons. ISBN 9780470056097.

  8. Harapanhalli RS. Chapter 18 - Regulatory considerations in the development of low-dose solid oral drug products. Formulation and Analytical Development for Low-Dose Oral Drug Products. Zheng J editor. 2009 John Wiley & Sons. ISBN 9780470056097.

  9. Garcia TP, Prescott JK. Chapter 4 - Blending and Blend Uniformity. Pharmaceutical Dosage Forms: Tablets, Third Edition Volume 1: Unit Operations and Mechanical Properties. Augsburger LL, Hoag SW editors. 2008 Informa Health Care. ISBN 0849390141.

  10. Simons SJR. Chapter 27 - Liquid Bridges in Granules. Granulation, Volume 11 (Handbook of Powder Technology). Salman AD, Hounslow M, Seville JPK editors. 2007 Elsevier. ISBN 0444518711.

  11. Franchini MK. Particle Engineering. Encyclopedia of Pharmaceutical Technology. Third Edition. Swarbrick J ed. 2007 Informa Health Care ISBN 9780849393990.

  12. Niazi SK. Handbook of Preformulation: Chemical, Biological, and Botanical Drugs. 2006 CRC Press. ISBN 0849371937.

  13. Gibson M. Pharmaceutical Preformulation and Formulation:  A Practical Guide from Candidate Drug Selection to Commercial Dosage Form. 2004 Informa Health Care. ISBN 1574911201.

  14. Stricker H. Arzneiformen-Entwicklung. 2003 Springer. ISBN 3540000682.

  15. Carstensen JT. Advanced Pharmaceutical Solids. 2001 CRC Press. ISBN 0824704312.

Johnson KC. Dissolution and absorption modeling: model expansion to simulate the effects of precipitation, water absorption, longitudinally changing intestinal permeability, and controlled release on drug absorption. Drug Dev Ind Pharm. 29 (2003) 833-42.

  1. Thelen K, Coboeken K, Willmann S, Burghaus R, Dressman JB, Lippert J. Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part 1: oral solutions. J Pharm Sci. DOI 10.1002/jps.22726.

  2. Johnson KC. Comparison of methods for predicting dissolution and the theoretical implications of particle-size-dependent solubility. J Pharm Sci. DOI 10.1002/jps.22778.

  3. Willmann S, Thelen K, Becker C, Dressman JB, Lippert J. Mechanism-based prediction of particle size-dependent dissolution and absorption: Cilostazol pharmacokinetics in dogs. European Journal of Pharmaceutics and Biopharmaceutics. 76 (2010) 83-94.

  4. Sugano K. Computational oral absorption simulation of free base drugs. Int J Pharm. DOI 10.1016/j.ijpharm.2010.07.027.

  5. Sugano K. Aqueous boundary layers related to oral absorption of a drug: from dissolution of a drug to carrier mediated transport and intestinal wall metabolism. Molecular Pharmaceutics. DOI 10.1021/mp1001119.

  6. Dai W-G. In vitro methods to assess drug precipitation. Int J Pharm. 393 (2010) 1-16.

  7. Sugano K. Possible reduction of effective thickness of intestinal unstirred water layer by particle drifting effect. Int J Pharm. 387 (2010) 103-109.

  8. Takano R, Takata N, Shiraki K, Higo S, Hayashi Y, Yamashita S. A Theoretical-Empirical Analysis on the Initial Dissolution Rate of Drugs from Polydispersed Particles. Biol Pharm Bull. 32 (2009) 1885-1891.

  9. Jamei M, Turner D, Yang J, Neuhoff S, Polak S, Rostami-Hodjegan A, Tucker G. Population-based mechanistic prediction of oral drug absorption. The AAPS Journal. 11 (2009) 225-237.

  10. Sugano K. Calculation of Fraction of Dose Absorbed: Comparison Between Analytical Solution Based on One Compartment Steady State Concentration Approximation and Dynamic Seven Compartment Model. Chem-Bio Informatics Journal. 9 (2009) 75-93.

  11. Sugano K. Introduction to computational oral absorption simulation. Expert Opin Drug Metab Toxicol. 5 (2009) 259-293.

  12. Jamei M, Dickinson GL, Rostami-Hodjegan A. A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of 'bottom-up' vs 'top-down' recognition of covariates. Drug Metab Pharmacokinet. 24 (2009) 53-75.

  13. Golovenko NY, Borisyuk IY. Physiological models of drug bioavailability based on the mechanisms of their absorption. Журн. АМН України. 15 (2009) 32–49.

  14. Sugano K. Theoretical comparison of hydrodynamic diffusion layer models used for dissolution simulation in drug discovery and development. Int J Pharm. 363 (2008) 73-77.

  15. Butcher JC, Garg S, Kim D, Sharma P. A modified approach to predict dissolution and absorption of polydisperse powders. Pharm Res. 25 (2008) 2309-2311.

  16. Jinno J, Kamada N, Miyake M, Yamada K, Mukai T, Odomi M, Toguchi H, Liversidge GG, Higaki K, Kimura T. In vitro-in vivo correlation for wet-milled tablet of poorly water-soluble cilostazol. J Control Release. 130 (2008) 29-37.

  17. Pole DL. Physical and biological Considerations for the Use of Nonaqueous Solvents in Oral Bioavailability Enhancement. J Pharm Sci. 97 (2008) 1071-1088.

  18. Sugano K, Okazaki A, Sugimoto S, Tavornvipas S, Omura A, Mano T. Solubility and dissolution profile assessment in drug discovery. Drug Metab Pharmacokinet. 22 (2007) 225-254.

  19. Kallen A. A simple absorption model for dose-escalating studies. Journal of Pharmacokinetics and Pharmacodynamics. 34 (2007) 251-261.

  20. Stegemann S, Leveiller F, Franchi D, de Jong H, Linden H. When poor solubility becomes an issue: from early stage to proof of concept. European Journal of Pharmaceutical Sciences. 31 (2007) 249-261.

  21. Jinno J, Kamada N, Miyake M, Yamada K, Mukai T, Odomi M, Toguchi H, Liversidge GG, Higaki K, Kimura T. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J Control Release. 111 (2006) 56-64.

  22. Thombre AG. Assessment of the feasibility of oral controlled release in an exploratory development setting. Drug Discov Today. 10 (2005) 1159-66.

  23. Sertsou G. Analytical derivation of time required for dissolution of monodisperse drug particles. J Pharm Sci. 93 (2004) 1941-4.

Book citations for Johnson

  1. Zhang H, Surian JM. Chapter 3 - Biopharmaceutic Consideration and Assessment for Oral Controlled Release Formulations. Oral Controlled Release Formulation Design and Drug Delivery: Theory to Practice. ed. Wen H, Park K. 2010 John Wiley and Sons. ISBN 9780470253175.

  2. Brewster ME, Mackie C, Noppe M, Lampo A, Loftsson T. Chapter 8 - The use of solubilizing excipients and approaches to generate toxicology vehicles for contemporary drug pipelines. Solvent Systems and Their Selection in Pharmaceutics and Biopharmaceutics.  ed. Augustinjns P, Brewster ME. 2007 American Association of Pharmaceutical Scientists. ISBN 9780387691497.

  3. Johnson KC. Chapter 1 - Dissolution: Fundamentals of In Vitro Release and the Biopharmaceutics Classification System. Pharmaceutical Product Development In Vitro-In Vivo Correlation. ed. Chilukuri DM, Sunkara G, Young D. 2007 Informa Health Care. ISBN 0849338271.

Kevin C. Johnson, "Particle Size of Drug Substance and Product Content Uniformity - Theoretical Considerations," in Formulation and Analytical Development for Low-Dose Oral Drug Products, edited by Jack Zheng, copyright 2009 by John Wiley & Sons, ISBN 9780470056097.

Huang CY, Ku MS. Prediction of drug particle size and content uniformity in low-dose solid dosage forms. Int J Pharm. 383 (2010) 70-80.

Kevin C. Johnson, "Dissolution: Fundamentals of In Vitro Release and the Biopharmaceutics Classification System" in Pharmaceutical Product Development In Vitro-In Vivo Correlation, edited by Dakshina Murthy Chilukuri, Gangadhar Sunkara, and David Young, copyright 2007 by Informa Healthcare USA, Inc. ISBN 10:0-8493-3827-1.

Dai W-G. In vitro methods to assess drug precipitation. Int J Pharm. 393 (2010) 1-16.

Tolman JA, Williams RO III. Advances in the Pulmonary Delivery of Poorly Water-Soluble Drugs: Influence of Solubilization on Pharmacokinetic Properties. Drug Dev Ind Pharm. 36 (2010) 1-30.

Shamblin SL. Chapter 9 - Controlled Release Using Bilayer Osmotic Tablet Technology: Reducing Theory to Practice. Oral Controlled Release Formulation Design and Drug Delivery: Theory to Practice. ed. Wen H, Park K. 2010 John Wiley and Sons. ISBN 9780470253175.

 

© 2002-2009 Intellipharm, LLC